What diseases does Vemurafenib treat?

Vemurafenib (Vemurafenib) can be used to treat unresectable or metastatic melanoma and Erdheim-Chester disease with BRAF V600E mutations (it is an orphan drug designated by the FDA for this purpose). Before initiating treatment, an FDA-approved in vitro diagnostic test (e.g., COBAS 4800 BRAF V600 Mutation Test) is required to confirm the presence of the BRAF V600E mutation.

The American Society of Clinical Oncology (ASCO) states that patients with BRAF V600 mutation-positive cutaneous melanoma can be offered treatment with BRAF/MEK inhibitors (eg, dabrafenib-tramatinib, vemurafenib-cobimetinib) alone or in combination. For patients who have progressed on first-line programmed death receptor-1 (PD-1) inhibitors, BRAF/MEK inhibitor combination therapy can be offered. For patients who have progressed on first-line combined BRAF/MEK inhibitor therapy, PD-1 inhibitor therapy can be offered. Patients with mucosal melanoma can receive the same treatment as patients with cutaneous melanoma regimen. BRAF or MEK inhibitors have been used as first-line treatment for patients with life-threatening (eg, central nervous system or cardiac involvement) Erdheim-Chester disease. The most common second-line systemic or salvage treatments for Erdheim-Chester disease include BRAF or MEK inhibitors.

Vemurafenib The original drug has been launched in China and has entered the scope of medical insurance. The price of 240mg*56 tablets per box may be around 7,000 yuan, which is very expensive. The Turkish version of Vemurafenib Original drug listed overseas, specifications240mg*56 tablets, may cost more than 2,000 yuan per box (the price may fluctuate due to exchange rates), which is relatively cheap. There is currently no generic version of Vemurafenib on the market. For more drug information and specific prices, please consult a medical consultant.